Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alloimmunization to platelet antigens.

D J Nugent1

  • 1Department of Pediatric Hematology-Oncology, University of Wisconsin, Madison.

Seminars in Hematology
|July 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Prevention of Bleeding Complications in Neonates With Liver Failure Undergoing Surgery Using Recombinant Factor VIIa.

Hematology (Amsterdam, Netherlands)·2016
Same author

Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.

Haemophilia : the official journal of the World Federation of Hemophilia·2014
Same author

Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.

Haemophilia : the official journal of the World Federation of Hemophilia·2014
Same author

Screening for von Willebrand disease in children: a case-control study.

Journal of thrombosis and haemostasis : JTH·2011
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Alloantibodies cause low platelets and bleeding. Intravenous immunoglobulin (IVIG) is used for treatment, but may only benefit critically ill patients when combined with HLA-matched platelets.

Area of Science:

  • Immunology
  • Hematology
  • Transfusion Medicine

Background:

  • Alloantibodies to platelet-specific antigens are implicated in thrombocytopenia and bleeding.
  • Immune thrombocytopenic disorders, such as neonatal alloimmune thrombocytopenia (NATP) and post-transfusion purpura (PTP), are significant clinical challenges.
  • Intravenous immunoglobulin (IVIG) is a cornerstone therapy for these conditions.

Purpose of the Study:

  • To review the role of IVIG in managing alloantibody-mediated thrombocytopenia.
  • To evaluate the efficacy of IVIG in patients with refractory responses to random-donor platelets.
  • To explore potential therapeutic strategies for multiply transfused patients with alloantibodies.

Main Methods:

  • Literature review focusing on IVIG efficacy in alloantibody-mediated thrombocytopenia.

Related Experiment Videos

  • Analysis of treatment outcomes in patients with NATP and PTP.
  • Examination of responses to random-donor platelets versus HLA-matched platelets in refractory cases.

    • Main Results:

    • IVIG is a recognized treatment for NATP and PTP.
    • Refractory patients receiving random-donor platelets did not show improved responses with IVIG.
    • Critically ill and bleeding patients might benefit from IVIG combined with HLA-matched platelets.

    Conclusions:

    • IVIG remains crucial for managing alloantibody-induced thrombocytopenia.
    • The utility of IVIG in refractory cases requires further investigation.
    • Combination therapy with IVIG and HLA-matched platelets shows promise for specific patient populations.